Feasibility of SBIRT-PN

计划入组 86 人 · 首次发布于 2017 年 2 月 17 日

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

计划入组 120 人 · 首次发布于 2002 年 5 月 31 日

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

计划入组 240 人 · 首次发布于 2002 年 6 月 17 日

PN-032/PN-056

(PN-152,243)/PN-196,444

PN-10943

Commodore Metals Corp

Protagonist Therapeutics

United States

Stephanie Miller

United States

Bio Visu's U.S. Sales Surge Past 7 Billion Won as ECM Skin Booster Business Fuels Global Expansion

FDA Approves Obagi saypha MagIQ Injectable Hyaluronic Acid Filler, Marking Waldencast's Entry into US Dermal Filler Market

Mirdametinib Demonstrates Significant Tumor Reduction and Improved Quality of Life in NF1-Associated Plexiform Neurofibroma